Hailshadow
Sarepta Therapeutics (shares (Nasdak:SRPTIt fell on the market on Thursday after news related to a clinical seizure requested by the European Union drug organizer, the European Pharmaceutical Agency (EMA), in clinical studies that involve the genetic therapy of the company.
Sarepta (Nasdak:SRPTArrows
https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1042202100/image_1042202100.jpg?io=getty-c-w750
Source link